Neurotensin receptors and dopamine transporters: Effects of MPTP lesioning and chronic dopaminergic treatments in monkeys
- 29 April 1999
- Vol. 32 (3) , 153-164
- https://doi.org/10.1002/(sici)1098-2396(19990601)32:3<153::aid-syn2>3.0.co;2-x
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptakeNeuroscience Letters, 1994
- Neurotensin receptor interaction with dopaminergic systems in the guinea-pig brain shown by neurotensin receptor antagonistsEuropean Journal of Pharmacology, 1994
- Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeysBrain Research, 1992
- Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: A quantitative autoradiographic study using [3H]mazindolNeuroscience, 1992
- Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivoEuropean Journal of Pharmacology, 1991
- Neurotensin receptors in parkinson's disease and progressive supranuclear palsy: an autoradiographic study in basal gangliaNeuroscience, 1990
- Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeysBrain Research, 1986
- Peptides and Parkinson's diseaseTrends in Neurosciences, 1985
- Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson's diseaseAnnals of Neurology, 1985
- A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.Proceedings of the National Academy of Sciences, 1983